You are here: Industry Insights > CAR-T

News List

Established Pharmaceutical Company Makes a High-profile Entrance with "Unlimited" R&D Investment, Signaling an Imminent Explosion in This Emerging Field xiaobin
December 20, 2024
Recently, Northeast Pharm announced its plan to acquire a 70% stock equity in Dingcheng Taiyuan for a total cash consideration of approximately RMB 187 million, thereby obtaining controlling stake in the company.
Research progress of dual-target CAR-T in China from the perspective of the ASCO 2023 Xiaobin/PharmaSources
June 27, 2023
At the ASCO this year, Gracell Bio announced the long-term follow-up data of its multi-center clinical study of CAR-T therapy with GC012F for recurrent/refractory multiple myeloma (R/R MM) in the form of oral report at the annual meeting.
Going Global Successfully! BCMA CAR-T of Legend Biotech is Approved by FDA for Marketing! PharmaSources/Small pill
March 16, 2022
On February 28 local time, LEGN.US officially announced in Somerset, New Jersey, U.S., that its self-developed BCMA-targeted CAR-T therapy, ciltacabtagene autoleucel (trade name: CARVYKTI®), abbreviated as Cilta-cel, was approved for marketing by the FDA.
Cell Therapy Expected to Treat Solid Tumors in the Future as a CAR-T cell Therapy Clinical Trial for Treating Gastric and Pancreatic Cancers was Accepted PharmaSources/Xiaobin
June 17, 2020
CAR-T cells can be easily led to cancer cells by relying on this target, to wipe out cancer. However, there is no such apparent target that only exists in tumor cells instead of normal cells in solid tumors.
Immuno-Oncology: Current Market Landscape and Future Trends（2） Neeta Ratanghayra
September 18, 2024
CAR-T Therapy & Antibody–Drug Conjugates.
T-CURX GmbH Announces Appointment of Two Industry Leaders to its Board of Directors PharmaSources
August 28, 2023
On August 28, 2023,T-CURX GmbH announces the appointments of Dr. Hans-Peter (HP) Gerber, PhD, as Chairman and of Dr. Bernd Eschgfäller, PhD, as an independent Board member.
T-CURX GmbH Announces Senior Leadership Appointments to Significantly Bolster Clinical Team PharmaSources
June 07, 2023
Appointments of co-founder Professor Michael Hudecek as Chief Medical Officer and Dr. Karl Schumacher as Chief Clinical Officer.
ProBioGen Launches Their Lentivirus Packaging Cell Line Lenti.RiGHT - A Shortcut to Successful Lentivirus Manufacturing PharmaSources
May 18, 2023
May 17, 2023，ProBioGen announced the launch of their lentivirus (LV) packaging cell line Lenti.RiGHT as a new platinum standard for LV production at this year's PEGS Boston 2023.
Oxford Biomedica and Novartis extend lentiviral vector manufacturing agreement CPhIonline
December 15, 2021
The new agreement extends to 2028 and allows Oxord Biomedica to work with other potential partners across all CAR-T targets
Inceptor Bio Acquires Arranta Bio’s Gainesville, FL GMP Facility ContractPharma
November 01, 2021
Inceptor Bio has entered an agreement to acquire Arranta Bio’s 29,000 square foot process development and GMP clinical manufacturing facility and the transfer of a core operating team to establish cell therapy...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 13 14 Next page